Data may be delayed — last successful sync 2026-09-26 (18 days ago). Figures reflect the most recent completed ingest.
Company profile
Korsana Biosciences, Inc.
NASDAQ: KRSA · Healthcare · Medical - Pharmaceuticals
#792 of 1,417 Healthcare companies by revenue47th-percentile growth
EA Score
47DFH 46DQ —GM 61SS 21
v0.1 · 45/100 weight · provisional
↑ balance-sheet leverage, 3-yr revenue growth · ↓ listing tenure, workforce scale
Methodology →Revenue TTM
$1.9M
Rev growth YoY (TTM)
-12.6%
Net income (FY)
-$3.5M
Employees
1
as of 2026-09-13
Market cap
$122.7M
as of 2026-09-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.1M$2.1M2025
Net income-$3.5M-$3.5M2025
Operating income-$5.0M-$5.0M2025
Total assets$10.0M$10.0M2025
Liabilities$900.0k$900.0k2025
Equity$9.1M$9.1M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2024
By product
License Agreement88%
License13%
By geography
Not disclosed.
The read
What is Korsana Biosciences, Inc.’s revenue?
Korsana Biosciences, Inc. booked $2.1M in FY2025 revenue, growing 3.7% year over year — about the middle of the pack among Healthcare companies we track, at a -170.1% net margin.
Peers · Healthcare
BNB Plus Corp.33DGeneLink, Inc.——Aeolus Pharmaceuticals, Inc.——Cyclerion Therapeutics, Inc.40DHealthLynked Corp.34D20/20 Biolabs Inc.30DNeighbors
Middlesex →Key facts
CEORegina Graul
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersCambridge, MA
ExchangeNASDAQ: KRSA
Employees1
IPO date2026-09-09
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.